Krystal Biotech, Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical…
Biotechnology
US, Pittsburgh [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -65.67 | 232.41 | 676.94 | |
| Graham Fair Price | -66.97 | 4.58 | 13.85 | |
| PEG | -1213.54 | -14.80 | -1.13 | |
| Price/Book | 38.88 | 6.23 | 4.49 | |
| Price/Cash Flow | -11.52 | 340.57 | -384.91 | |
| Prices/Earnings | 1229.53 | 1336.35 | 100.51 | |
| Price/Sales | 32.77 | 110.10 | 82.92 | |
| Price/FCF | -11.52 | 340.57 | -384.91 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Bad
Fundamentals
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 5.63 | 0.95 | 0.90 | |
| Operating Margin | 98.38 | -0.15 | 0.07 | |
| ROA | -89.72 | < 0.005 | 0.01 | |
| ROE | 0.01 | < 0.005 | -89.55 | |
| ROIC | < 0.005 | 0.04 | 979.40 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.02 | -0.03 | 9.49 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 1.12 | -3.13 | 179.29 | |
| EPS QOQ | -0.89 | -0.90 | -1.22 | |
| FCF QOQ | 0.61 | 2.61 | 331.33 | |
| Revenue QOQ | 3.93 | 0.07 | -98.12 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 143.59 | 410.64 | 185.97 | |
| Days Sales Outstanding (DSO) | 89.78 | 92.42 | 2.94 | |
| Inventory Turnover | 0.63 | 0.22 | -65.03 | |
| Debt/Capitalization | 0.01 | < 0.005 | -4.92 | |
| Quick Ratio | 17.35 | 12.29 | -29.19 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 27.64 | 28.25 | 2.19 | |
| Cash | 18.89 | 19.02 | 0.69 | |
| Capex | -0.07 | -0.04 | 32.09 | |
| Free Cash Flow | -0.32 | 0.52 | 60.40 | |
| Revenue | 1.50 | 1.60 | 6.89 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Best
Fundamentals
Financial Health
06 - Financial Health ·
Bad